Factors Associated With Severity of COVID-19 Disease in Vaccinated Patients

Tamanna Bahar, Shaila Rahman, R. Anne, Zulfia Zinat Chowdhury, Mohammad Murad Hossain, Sanzida Akter, Mohammad Ali, Amit Wazib
{"title":"Factors Associated With Severity of COVID-19 Disease in Vaccinated Patients","authors":"Tamanna Bahar, Shaila Rahman, R. Anne, Zulfia Zinat Chowdhury, Mohammad Murad Hossain, Sanzida Akter, Mohammad Ali, Amit Wazib","doi":"10.3329/jdmc.v31i2.73148","DOIUrl":null,"url":null,"abstract":"Background: Vaccines are considered the most promising approach for restraining the COVID- 19 pandemic. We aimed to identify the disease profile and risk of severe disease despite vaccination. Methods: A cross-sectional study was done from June 2021 to August 2021 in the COVID-19 dedicated hospitals in Dhaka. Total 169 RT-PCR positive adult patients were enrolled by a purposive sampling method who had completed two vaccine doses of COVID-19. Disease profile and severity was identified according to the national guideline of Bangladesh. Results: Of the 169 patients, 19 (11%) had severe diseases. The mean age of the study participants was 50.46 (±14.03) year. The mean age of severely diseased patients was higher than that of non-severe disease 62.63 (±8.27) vs 48.91 (±13.86), p-value <0.0001. The overall mortality was 8 (4.7%). In univariate analyses, being elderly (e”60years) (cOR 6.14, 95% CI 2.09-18.03; p-value <0.0001) and male (cOR 5.06, 95% CI 1.13-2274; p-value <0.02 and having DM (cOR 32.94, 95% CI 4.28-253.69; p-value <0.0001, HTN (cOR 2.91, 95% CI 1.05-8.07; pvalue < 0.034, OAD (cOR 3.47, 95% CI 1.09-11.07; p-value < 0.044, IHD (cOR 7.54, 95% CI 2.67-21.31; p-value <0.0001, and CKD (cOR 26.43, 95% CI 4.69-148.92; p-value <0.0001were identified as factors related to severe disease of COVID-19. In multivariate analyses, DM (aOR 13.9, 95% CI 1.5-130.1; p-value <0.021, OAD (aOR 7.9, 95% CI 1.2-50.1; p-value <0.03, IHD (aOR 7.4, 95% CI 1.6-34.4; p-value < 0.011, and CKD (aOR 41.9, 95% CI 2.6-667.4; p-value < 0.008 were independently associated with severe disease. Conclusion: Vaccines against COVID-19 are showing a significant decrease in severity disease. Control of chronic diseases, exposure prevention and mass vaccination should be the main concern to mitigate the severity.\nJ Dhaka Med Coll. 2022; 31(2) : 220-225","PeriodicalId":320976,"journal":{"name":"Journal of Dhaka Medical College","volume":"112 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dhaka Medical College","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/jdmc.v31i2.73148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Vaccines are considered the most promising approach for restraining the COVID- 19 pandemic. We aimed to identify the disease profile and risk of severe disease despite vaccination. Methods: A cross-sectional study was done from June 2021 to August 2021 in the COVID-19 dedicated hospitals in Dhaka. Total 169 RT-PCR positive adult patients were enrolled by a purposive sampling method who had completed two vaccine doses of COVID-19. Disease profile and severity was identified according to the national guideline of Bangladesh. Results: Of the 169 patients, 19 (11%) had severe diseases. The mean age of the study participants was 50.46 (±14.03) year. The mean age of severely diseased patients was higher than that of non-severe disease 62.63 (±8.27) vs 48.91 (±13.86), p-value <0.0001. The overall mortality was 8 (4.7%). In univariate analyses, being elderly (e”60years) (cOR 6.14, 95% CI 2.09-18.03; p-value <0.0001) and male (cOR 5.06, 95% CI 1.13-2274; p-value <0.02 and having DM (cOR 32.94, 95% CI 4.28-253.69; p-value <0.0001, HTN (cOR 2.91, 95% CI 1.05-8.07; pvalue < 0.034, OAD (cOR 3.47, 95% CI 1.09-11.07; p-value < 0.044, IHD (cOR 7.54, 95% CI 2.67-21.31; p-value <0.0001, and CKD (cOR 26.43, 95% CI 4.69-148.92; p-value <0.0001were identified as factors related to severe disease of COVID-19. In multivariate analyses, DM (aOR 13.9, 95% CI 1.5-130.1; p-value <0.021, OAD (aOR 7.9, 95% CI 1.2-50.1; p-value <0.03, IHD (aOR 7.4, 95% CI 1.6-34.4; p-value < 0.011, and CKD (aOR 41.9, 95% CI 2.6-667.4; p-value < 0.008 were independently associated with severe disease. Conclusion: Vaccines against COVID-19 are showing a significant decrease in severity disease. Control of chronic diseases, exposure prevention and mass vaccination should be the main concern to mitigate the severity. J Dhaka Med Coll. 2022; 31(2) : 220-225
疫苗接种患者 COVID-19 疾病严重程度的相关因素
背景:疫苗被认为是抑制 COVID- 19 大流行的最有希望的方法。我们的目的是确定疾病概况和接种疫苗后患严重疾病的风险。研究方法2021 年 6 月至 2021 年 8 月在达卡的 COVID-19 专用医院进行了一项横断面研究。通过有目的的抽样方法,共招募了 169 名 RT-PCR 阳性的成年患者,这些患者已接种过两剂 COVID-19 疫苗。根据孟加拉国国家指南确定了疾病概况和严重程度。结果:在 169 名患者中,19 人(11%)患有严重疾病。研究参与者的平均年龄为 50.46 (±14.03) 岁。重症患者的平均年龄为 62.63(±8.27)岁,非重症患者为 48.91(±13.86)岁,P 值小于 0.0001。总死亡率为 8(4.7%)。在单变量分析中,老年人(e "60 岁)(cOR 6.14,95% CI 2.09-18.03;p 值<0.0001)和男性(cOR 5.06,95% CI 1.13-2274;p 值<0.02)以及患有 DM(cOR 32.94,95% CI 4.28-253.69;p 值<0.0001)、高血压(cOR 2.91,95% CI 1.05-8.07;p 值<0.0001)的患者死亡率最高。P值<0.034、OAD(cOR 3.47,95% CI 1.09-11.07;P值<0.044)、IHD(cOR 7.54,95% CI 2.67-21.31;P值<0.0001)和CKD(cOR 26.43,95% CI 4.69-148.92;P值<0.0001)被确定为与COVID-19严重疾病相关的因素。在多变量分析中,DM(aOR 13.9,95% CI 1.5-130.1;p-value <0.021)、OAD(aOR 7.9,95% CI 1.2-50.1;p-value <0.03)、IHD(aOR 7.4,95% CI 1.6-34.4;p-value <0.011)和 CKD(aOR 41.9,95% CI 2.6-667.4;p-value <0.008)与严重疾病独立相关。结论COVID-19疫苗可显著降低疾病的严重程度。控制慢性疾病、预防接触和大规模接种疫苗应成为减轻疾病严重程度的主要关注点。2022; 31(2) : 220-225
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信